Tuesday, March 21, 2023
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home National

Bharat Biotech seeks DCGI’s permission to conduct Covaxin booster trials in 2-18 age group

by
11 months ago
in National
A A
Bharat Biotech seeks DCGI’s permission to conduct Covaxin booster trials in 2-18 age group
Share on FacebookShare on Twitter

By Shalini Bhardwaj

New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.

The company has applied for permission a week ago. It has already conducted trials in the age group of 2-18 for two doses of Covaxin.

Recently, Bharat Biotech has also received an Emergency Use Authorisation (EUA) approval for 6-12 years old children for two doses.

Bharat Biotech has also applied for the EUA for the 2-5 years old but Subject Expert Committee (SEC) has asked for more data.

Bharat Biotech is the first company in India who had applied for permission from DCGI to conduct trials of a booster dose in the 2-18 age group.

Currently, the Covaxin is under the national COVID vaccination programme for the above 15-18 age group for two doses and above 18 years old for a precaution dose.

The trials for Bharat Biotech’s intranasal booster on a heterologous group are under trial, according to the sources data collection process is over for the age group above 18 years. (ANI)

ShareTweetSendShareSend

Latest News

Chhattisgarh CM launches Mukhyamantri Vriksh Sampada Yojana on occasion of World Forest Day

We fulfilled five guarantees given to people during 100 days of Cong govt: CM Sukhu

Delhi HC issues notice to Telecom Department on former Justice Quddusi’s plea

NIA files first chargesheet in one of three-gangster nexus cases, 12 individuals named

Second anti-submarine warfare craft launched in Kolkata

Indian Minorities Foundation launched to counter “false narrative against country” by anti-India elements

J-K terrorism conspiracy case: NIA names handicrafts dealer and Hizb-ul-Mujahideen worker as 27th accused in fresh charge-sheet

Meet Hina Chaudhary, highly educated female entrepreneur of Kashmir valley

23 individuals designated as terrorists under UAPA in last one year

10 mobile phones, tobacco seized in Delhi’s Rohini jail

By Shalini Bhardwaj

New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.

The company has applied for permission a week ago. It has already conducted trials in the age group of 2-18 for two doses of Covaxin.

Recently, Bharat Biotech has also received an Emergency Use Authorisation (EUA) approval for 6-12 years old children for two doses.

Bharat Biotech has also applied for the EUA for the 2-5 years old but Subject Expert Committee (SEC) has asked for more data.

Bharat Biotech is the first company in India who had applied for permission from DCGI to conduct trials of a booster dose in the 2-18 age group.

Currently, the Covaxin is under the national COVID vaccination programme for the above 15-18 age group for two doses and above 18 years old for a precaution dose.

The trials for Bharat Biotech's intranasal booster on a heterologous group are under trial, according to the sources data collection process is over for the age group above 18 years. (ANI)

No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science